Losartan potassium
Angiotensin AT1 receptor antagonist. In clinical trials to treat COVID-19.
- Datasheet: view or download
- Applications:Approved drug (U.S.); in COVID-19 clinical trials
Biochemicals & reagents
124750-99-8
1) Merck 14:5583 2) Chiu et al. (1990), Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent; J. Pharmacol. Exp. Ther., 252 711 3) McIntyre et al. (1997), Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of it’s efficacy and safety in essential hypertension; Pharmacol. Ther., 74 181 4) Diop-Frimpong et al. (2011), Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors; Proc. Natl. Acad. Sci. USA, 108 2909 5) Pantazi et al. (2015), Losartan activates sirtuin 1 in rat reduced-size orthotopic liver transplantation; World J. Gastroenterol., 21 8021 6) Kumar et al. (2015), Neuroprotective mechanism of losartan and its interaction with nimesulide against chronic fatigue stress; Inflammopharmacology, 23 291 7) Miguel-Carrasco et al. (2017), Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites; Sci. Rep. 7 41865
461.01
-20°C (des.)
Losartan is non-peptide angiotensin II receptor antagonist (1,2) which is a clinically relevant antihypertensive agent (3). This compound inhibits collagen I synthesis (4) and induces SIRT1 expression and activity and reduces hepatic injury in a rat reduced-size orthotopic liver transplantation model (5). It displays neuroprotective effects along with nimesulide against chronic fatigue stress (6) as well as myocardial antifibrotic activity (7).